Introduction {#S1}
============

*Stenotrophomonas maltophilia* is a robust, non-sporulating, obligate aerobe Gram-negative bacillus ([@B16]). The genus name *Stenotrophomonas* was originally chosen due to the perceived limited nutritional range of the bacterium ([@B75]), though many studies have since shown an impressive metabolic versatility ([@B25]; [@B12]; [@B44]; [@B69]; [@B100]). *S. maltophilia* is often found in close association with plant rhizospheres where they actively promote plant growth through the secretion of growth-promoting compounds ([@B88]). This plant growth promotion is now being used commercially; *S. maltophilia* strains are used as biofertilizers due to their ability to fix nitrogen, produce growth-promoting plant hormones, and protect plant roots from phytopathogens ([@B85]). Additionally, the vast metabolic diversity observed in *S. maltophilia* enables these bacteria to be used in bioremediation, from heavy metal detoxification of soils and waterways to the degradation of insecticides and volatile organic compounds such as benzene. However, their widespread use in biotechnology and agriculture is problematic due to their ability to cause disease in humans ([@B11]).

*S. maltophilia* is an important multidrug resistant, opportunistic pathogen that is most commonly associated with pneumonia and bacteremia in immunocompromised patients. *S. maltophilia* has also been identified as the cause of soft tissue infections, osteomyelitis, meningitis, endocarditis, otitis and scleritis ([@B16]). Several risk factors are associated with *S. maltophilia* infections in the general population, including malignancy, human immunodeficiency virus, cystic fibrosis (CF), intravenous drug use, surgical and accidental trauma, prolonged hospitalization, mechanical ventilation, indwelling catheters, corticosteroids, immunosuppressive therapy, and treatment with broad-spectrum antibiotics ([@B2]). One study estimated the nosocomial mortality rates attributed to *S. maltophilia* bacteremia at 16.7%, and the overall mortality rate of patients infected with *S. maltophilia* was 25% ([@B70]). A recent study on the clinical outcomes of cancer patients with bloodstream infections (BSI) and pneumonia caused by *S. maltophilia* infections in Mexico City indicated that 31.6% died within the first month; 22.1% of the deaths were due to pneumonia and 9.5% were due to BSI ([@B103]). A similar study on BSI mortality rates associated with 937 German intensive care units found *S. maltophilia* infections had the highest mortality rates (28.4%), followed next by non-*albicans*-*Candida spp.* (27.1%) and *Pseudomonas aeruginosa* (25.8%) ([@B94]).

Due to a wide array of pathogenicity factors, *S. maltophilia* can be difficult to clear once an infection has been established. *S. maltophilia* pathogenicity mechanisms include swimming and twitching motility (from flagella and type IV pili, respectively), a DNA hypermutator mechanism, iron uptake transporters, biofilm formation, lipopolysaccharide (LPS), many extracellular enzymes encoded such as fibrolysin, lipases, esterase, DNase, RNase, proteases and lecithinase, type II protein secretion systems, host cell invasion, and quorum sensing signaling systems ([@B16]). In addition, clinical *S. maltophilia* isolate culture supernatants applied to Hep-2, HeLa, or Vero cells resulted in cytotoxic effects such as intensive rounding, loss of intercellular junctions, and membrane blebbing followed by cell death within 24 h ([@B36]). In some cases, endocytosis, hemolytic activity, and cell aggregation were observed, and the addition of protease inhibitors did not prevent cell cytotoxicity. LPS production was shown to be required for attachment to surfaces, and colonization and virulence in a rat lung model ([@B64]). As well, it was shown that an *O*-polysaccharide synthesis mutant was susceptible to complement-mediated cell killing ([@B18]). *S. maltophilia* can form biofilms on many surfaces such as glass, plastics, implanted medical devices, and lung epithelial cells ([@B48]; [@B81], [@B80]; [@B17]). A study focusing on the biofilm formation of CF-derived bronchial epithelial cell monolayers revealed that all *S. maltophilia* isolates were able to form biofilms on bronchial epithelial cells ([@B80]). Type-1 fimbriae genes have only been identified in clinical *S. maltophilia* isolates, which suggests they may play a direct role in the colonization of infected CF individuals ([@B71]). *In vitro* tissue culture assays have indicated the *S. maltophilia* fimbriae 1 (SMF-1) protein is important for adherence to eukaryotic cells and glass, and anti-SMF-1 antibodies inhibit adherence to eukaryotic cells and glass if the antibodies were applied during early stages of infection ([@B30]). The ability of *S. maltophilia* isolates to form biofilms and invade host cells contributes to the prolonged infections noted in hematology and oncology patients, despite aggressive antibiotic treatments ([@B57]).

Innate antibiotic resistance in *S. maltophilia* infections is a major contributing factor to treatment failure. Patients who receive the wrong antibiotic at initial infection diagnosis have an increased risk of mortality compared to patients who received appropriate *S. maltophilia* antibiotic treatment initially ([@B103]). *S. maltophilia* infections can be further complicated by the emergence of mutants with pleiotropic antibiotic resistance ([@B33]). Intrinsic resistance is attributed to mechanisms such as reduced membrane permeability ([@B66]), chromosomally encoded multidrug efflux pumps, and chromosomally encoded Qnr pentapeptide repeat proteins ([@B90]; [@B91]; [@B22]). Additionally, antibiotic inactivating enzymes such as inducible L1 and L2 β-lactamases ([@B105]; [@B28]; [@B74]), a TEM-2 β-lactamase from a Tn*1*-like transposon ([@B6]), and aminoglycoside- inactivating enzymes ([@B73]; [@B104]) have been identified in many *S. maltophilia* isolates. The L1 protein is a molecular class B zinc-dependent metallo-β-lactamase which hydrolyzes virtually all classes of β-lactams, including penicillins, cephalosporins and carbapenems ([@B5]), whereas the L2 protein is a molecular class A clavulanic acid-sensitive cephalosporinase ([@B23]). The drug of choice to treat *S. maltophilia* infections continues to be trimethoprim/sulfamethoxazole (TMP/SMX) ([@B26]; [@B106]), although resistance to TMP/SMX across clinical isolates is common (30.5%) ([@B72]). However, higher rates of TMP/SMX resistance, ranging from 16% to nearly 80%, have been noted in patients with cancer, CF, and in several specific countries ([@B23]; [@B87]). The majority of TMP/SMX resistance is due to the presence of a *sul* gene encoding a sulfonamide resistance protein located on a class 1 integron (sul1) ([@B8]; [@B27]), and also on insertion sequence common region (ISCR) elements (sul2) ([@B101]) rather than through the overexpression of efflux pumps. A *dhfr* gene encoding a dihydrofolate reductase associated with a class 1 integron has also been shown to cause some level of resistance against TMP/SMX ([@B47]), along with the activity from several RND family efflux pumps, although not to the same degree as the resident *sul* genes ([@B49]; [@B59]; [@B89]). Thus, research into alternative treatment options is critical due to increased resistance to TMP/SMX noted with specific comorbidities and geographic locations.

Related to this high-level antibiotic resistance, *S. maltophilia* is also capable of tolerating biocides and harsh environments, which makes this bacterium difficult to eradicate from hospital settings. Nosocomial isolation sources for *S. maltophilia* include ultra-pure water, hemodialysis water, nebulizers, hand-washing soap, hospital antiseptic solution, chlorhexidine-cetrimide topical antiseptic solution, hypochlorite cleaners, triclosan, sodium dodecyl sulfate, and antiseptics containing quaternary ammonium compounds ([@B16]; [@B52]). Non-clinical multidrug resistant isolates of *S. maltophilia* have also been recovered from environments such as soil, water, plants and food sources ([@B10]; [@B84]; [@B16]; [@B58]; [@B38]; [@B55]), and have the potential to cause community-acquired infections ([@B34]; [@B24]).

High levels of innate antibiotic resistance in *S. maltophilia* isolates highlights the need for alternative treatment options to combat these infections. The use of bacteriophages, or phages, as viruses specifically lytic toward bacteria, is being investigated as a viable option. Phage therapy requires the isolation and characterization of phages prior to their use as prophylactic or therapeutic agents. Phage therapy holds several advantages over traditional antibiotics ([@B99]; [@B19]; [@B40]). First, phages possess a narrow host range, only infecting a few strains within a species, enabling precise targeting of the treatment, and preventing disruption of the patient's normal microbiota. Second, phages are self-replicating, such that phage replication can significantly increase phage abundance at the site of the bacterial infection. Third, phages use a different mechanism of action to kill bacteria than chemical antibiotics, and so are virulent against antibiotic resistant bacteria. Fourth, few side effects have been reported during or after phage application, including immune responses, suggesting that higher organisms are adapted to the presence of phages within tissues or on body surfaces. In addition, the high abundance of phages in the environment make them relatively simple to isolate. As well, phages are relatively easy to manipulate through molecular approaches to create therapeutically enhanced phages which exhibit improved performance *in vivo*, and phage biology is becoming better understood such that the development of new therapeutic phages will progress more rapidly than it has in the past. Ideally, a therapeutic cocktail of multiple phages targeting several bacterial strains with different phage-receptors will be developed to increase the host range of the cocktail and protect against receptor-mutation mediated resistance ([@B19]; [@B40]).

Twenty phages specific to *S. maltophilia* have been isolated and characterized to date. Eleven phages (Sm1, IME13, IME15, S3, Sm14, ΦSMA5, DLP1, DLP2, DLP4, DLP5, DLP6) have been isolated and characterized specifically for their therapeutic potential. For example, the *Myoviridae* phage ΦSMA5 has an extensive host range successfully infecting 61 out of 87 strains tested ([@B21]), while Sm1 is the first *S. maltophilia* phage used in a murine model where it was found to provide 100% protection against *S. maltophilia* infection. The broad host range of ΦSMA5 and significant *in vivo* protection Sm1 provides in a murine model are promising examples of therapeutic phages that can be used for the treatment of antibiotic resistant *S. maltophilia* infections.

Materials and Methods {#S2}
=====================

Bacterial Strains and Growth Conditions {#S2.SS1}
---------------------------------------

Initial phage isolation was accomplished with five clinical *S. maltophilia* strains (D1585, D1571, D1614, D1576, D1568) from the Canadian *Burkholderia cepacia* complex Research and Referral Repository (CBCCRRR; Vancouver, BC, Canada). An additional 22 *S. maltophilia* clinical isolates were obtained from the Provincial Laboratory for Public Health - North (Microbiology), Alberta Health Services for host range analysis. Strains SMDP92 and ATCC 13637 were gifted by Dr. Jorge Giron. Strains were grown aerobically at 30°C on Luria-Bertani solid media until single colonies were visible (16--36 h) or in LB broth with shaking at 225 RPM.

Bacteriophage Isolation, Propagation, and Host Range {#S2.SS2}
----------------------------------------------------

The phage DLP3 (vB_SmaS_DLP_3) was isolated from soil collected in Edmonton, Alberta, Canada using host strain *S. maltophilia* D1571. No plants were associated with the soil sample. Approximately 10 ml of soil was mixed with 10 ml of LB broth, 1 ml of modified suspension media (SM) (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgSO4) and 100 μl of a D1571 overnight culture. The slurry was incubated overnight at 30°C with shaking at 225 RPM. The supernatant was filter-sterilized with a Millex-HA 0.45 μm syringe-driven filter (Millipore, Billerica, MA, United States) and stored at 4°C, as performed previously ([@B77], [@B79], [@B78]). A single plaque was picked to propagate a working-stock solution for analysis using top-agar overlays. Briefly, 100 μl of overnight D1571 culture and 100 μl DLP3 stock (∼10^9^ PFU/ml) were mixed and incubated for 5 min at room temperature then added to 3 ml of 0.7% LB top agar. The mixture was poured onto an LB plate and incubated for 18 h at 30°C. The top agar of plates showing confluent lysis was scraped into a 50 ml Falcon tube. A 3 ml aliquot of SM was added for each plate scraped and the slurry was shaken for 1 min followed by centrifugation (5 min at 10,000 × *g*) and filter sterilization. Host range analysis was performed on 29 *S. maltophilia* and 19 *Pseudomonas aeruginosa* strains using serially diluted DLP3 lysate into SM. A 10 μl aliquot of each concentration was spotted in triplicate onto a plate containing bacterial culture in a top-agar overlay and incubated overnight at 30°C.

Electron Microscopy {#S2.SS3}
-------------------

Phage lysate for electron microscopy was prepared using LB plates and top agar made with agarose and filter sterilized using a 0.22 μm filter. A carbon-coated copper grid was overlaid with 10 μl of phage lysate for 2 min then stained with 4% uranyl acetate for 30 s. A Philips/FEI (Morgagni) transmission electron microscope (TEM) with charge-coupled device camera at 80 kV (University of Alberta Department of Biological Sciences Advanced Microscopy Facility) was used to obtain TEM images. The capsid diameter, tail length and tail width of ten virions were measured using ImageJ and averages calculated using Microsoft Excel.

Phage DNA Isolation, Sequencing, and RFLP Analysis {#S2.SS4}
--------------------------------------------------

Genomic DNA was isolated from a high-titer DLP3 stock (10^9^ PFU/ml). Lysate was clarified by spinning 10,000 × *g* for 10 min and the supernatant was subsequently treated with 100 μl 100x DNase I buffer (1 M Tris--HCl, 0.25 M MgCl2, 10 mM CaCl2), 10 μl DNase I (Thermo Scientific, Waltham, MA, United States), 6 μl RNase (Thermo Scientific) and incubated 1 h at 37°C. A 400 μl aliquot of 0.5 M EDTA (pH 8.0), SDS (final concentration of 2%) and Proteinase K (final concentration of 400 μg/ml) was added followed by incubation at 55°C overnight. A 1/2 volume of 6 M NaCl was added and the solution was vortexed at high speed for 30 s followed by centrifugation at 17,900 × *g* for 30 min. The supernatant was transferred to a fresh tube with an equal volume of 100% isopropanol and stored at −20°C for at least 1 h to overnight. The DNA was pelleted with centrifugation at 17,900 × *g* for 20 min at 4°C followed by three 70% ethanol washes. The pellet was dried at room temperature and resuspended in nuclease-free water. Purity and concentrations of eluted DNA were checked with a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, United States). DLP3 genomic (gDNA) DNA was sequenced using both Illumina and Pacific Biosciences technologies. A Nextera XT library was generated for paired-end sequencing on MiSeq (Illumina) platform using MiSeq v2 reagent kit. Restriction fragment length polymorphism (RFLP) analysis was used with 15 FastDigest (Thermo Scientific) restriction enzymes: *Eco*RI, *Xba*I, *Bam*HI, *Hin*dIII, *Kpn*I, *Sma*I, *Sph*I, *Pst*I, *Sac*I, SaII, *Apa*I, *Cla*I, *Nde*I, *Spe*I, Xhol. Restriction reactions were set up using 1 μl FastDigest enzyme, 2 μl FastDigest restriction buffer, 1 μg of phage DNA and nuclease-free water to bring the final volume to 20 μl. Reactions were separated on a 0.8% (wt/vol) agarose gel in 1x TAE (pH 8.0).

Bioinformatic Analysis of the DLP3 Genome {#S2.SS5}
-----------------------------------------

A 96,852 bp contig assembled from the Illumina reads with SPAdes 3.8.0 was identified for further analysis. No gaps or ambiguous sites were found in the assembly, which has a mean coverage of 114 reads and Q40 of 93.8%. Prediction of open reading frames (ORFs) was accomplished with the GLIMMER plugin ([@B32]) for Geneious ([@B53]) using the Bacteria and Archaea setting, as well as GeneMarkS for phage ([@B13]). Conserved domain searches were performed using CD-Search with the CDD v3.16 -- 50369 PSSMs database ([@B62]). Phyre ([@B54]), HHblits ([@B86]; [@B112]) and ITASSER ([@B110]) were used to gain insights into possible functions of hypothetical proteins or to provide more support for putative functions. BLASTn and BLASTp were used to gain information on relatives based on genomic data and individual proteins, respectively ([@B4]). The NCBI non-redundant protein sequence and nucleotide collection databases (update dates for both: 2018/08/26) were used for the BLASTp and BLASTn searches, respectively. BLASTp results above 1.00E-03 were annotated as hypothetical proteins. tRNAs were identified using the general tRNA model with tRNAscan-SE software ([@B92]).

D1585 *pilT* Deletion Construction {#S2.SS6}
----------------------------------

A *pilT* clean deletion mutant of *S. maltophilia* D1585 was constructed using overlap-extension PCR and allele exchange as previously described ([@B63]). Briefly, regions upstream and downstream of the *pilT* gene in D1585 were PCR amplified using Phusion High-Fidelity DNA Polymerase (New England Biolabs) with primer pairs UpF-*Hin*dIII (GGGC**AAGCTT**CAGTACCTGCGGCTTCACTG) and UpR-OE (*CTCGAACAGGCGCTTGGACGCTTTGTTCTT*TACGG) for the upstream region, and DnF-OE (*AAGAACAAAGCGTC CAAGCGCCTGTTCGAG*TAAGG) and DnR-*Xba*I (GGGC **TCTAGA**CTTCAGCTTGTGGATCTCGC) for the downstream region. Overlap regions are italicized and restriction enzyme recognition sites are bolded. Following overlap-extension PCR, the deletion cassette was ligated into pEX18Tc and this plasmid, pD1585Δ*pilT*, was transformed into *E. coli* S17-1 for bacterial mating with D1585. Single crossover transconjugants were selected on LB agar containing 100 μg/mL tetracycline and merodiploid status was confirmed by colony PCR with *pilT* specific primers pilTF (GTTCCGTTGAATCAGGAGGC) and pilTR (GAGGGCATGTACCAGGAAAC). Positive merodiploids were grown in LB broth and plated on LB with 10% sucrose to select for double crossover Δ*pilT* mutants that were confirmed by colony PCR as above. For complementation, the D1585 *pilT* gene was cloned into pBBR1MCS using pilTF and pilTR primers with tails for *Hin*dIII and *Xba*I restriction enzymes (Thermo Fisher) to create pD1585*pilT*.

Phage Plaquing Assays {#S2.SS7}
---------------------

DLP3 plaquing ability on wildtype and mutant strains of D1585 and 280 was determined by spot assay on bacterial lawns as previously described ([@B63]). Briefly, bacterial strains were grown in 1/2 LB supplemented with 35 μg/mL chloramphenicol at 30°C with aeration at 225 RPM for 18 h. 100 μL of overnight culture was used in a top agar overlay containing 35 μg/mL chloramphenicol and allowed to solidify. DLP3 lysate standardized to 10^10^ PFU/mL on *S. maltophilia* D1571 was ten-fold serially diluted in SM to 10^3^ PFU/mL and 5 μL of each dilution was spotted on the prepared plates in triplicate. Plates were incubated upright at 30°C and imaged after 16 h. Each experiment was repeated in biological and technical triplicate.

Protein Isolation and Mass Spectrometry {#S2.SS8}
---------------------------------------

Isolation of DLP3 protein for SDS-PAGE analysis was accomplished following a protocol for the formation of ghost particles ([@B15]). Briefly, sterile DLP3 lysate (∼1 × 10^9^) was clarified twice with 10,000 × *g* centrifugations and treated with nucleases following the DNA isolation protocol described above. After the incubation, an equal volume of 10 M LiCl was added and the solution was incubated at 46°C for 10 min, followed by 10-fold dilutions into sterile Milli-Q water. The released DLP3 gDNA was digested with an addition of 10 mM MgCl~2~ and 50 U of RNase-free DNaseI per 1 × 10^12^ PFU. This solution was incubated overnight at 37°C, followed by ultracentrifugation at 28,700 × *g* for 1.2 h. The supernatant was discarded and pellets were resuspended with 100 μl SM. An aliquot of the sample was diluted in half with 2x Laemmli sample buffer (10% \[v/v\] beta-mercaptoethanol \[BME\], 6% \[w/v\] SDS, 20% \[v/v\] glycerol, 0.2 mg/ml bromophenol blue) and incubated 10 min at 99°C.

An SDS-PAGE gel with a 4% stack and a 7.5% resolving portion was made with 40% 37.5:1 acrylamide/bis-acrylamide solution (Bio-Rad) and fresh 10% ammonium persulfate. The gel was loaded into a Mini-PROTEAN electrophoresis chamber (Bio-Rad) using 1x running buffer. A 6 μl aliquot of PageRuler Plus Prestained Protein Ladder (Thermo Scientific) was used as a molecular weight standard and 6--12 μl of DLP3 ghost particles in 1x sample buffer was loaded into the remaining wells. The gel was run at 180 kV for 75 min and placed in Coomassie R-250 stain for 1 h with gentle rocking. The gel was destained over 2 h, with the destaining solution replaced every 30 min. The gel was placed in a 50 ml Falcon tube with Milli-Q to transport the gel for mass spectrometry analysis at the Alberta Proteomics and Mass Spectrometry (APM) facility located at the University of Alberta.

In-gel trypsin digestion was performed on the samples. The lane was cut into seven equal gel sections, destained twice in 100 mM ammonium bicarbonate/acetonitrile (ACN) (50:50), reduced (10 mM BME--100 mM bicarbonate) and then alkylated (55 mM iodoacetamide--100 mM bicarbonate). After dehydration, trypsin digestion (6 ng/μl) was allowed to proceed overnight at room temperature. Tryptic peptides were extracted from the gel using 97% water--2% acetonitrile--1% formic acid followed by a second extraction using 50% of the initial extraction buffer and 50% acetonitrile. Fractions containing tryptic peptides were resolved and ionized using nanoflow high-performance liquid chromatography (HPLC) (Easy-nLC 1000; Thermo Scientific) coupled to a Q Exactive Orbitrap mass spectrometer (MS) (Thermo Scientific). Nanoflow chromatography and electrospray ionization were accomplished by using a Pico- Frit fused silica capillary column (ProteoPepII; C18) with a 100-μm inner diameter (New Objective) (300 Å, 5 μm pore size). Peptide mixtures were injected onto the column at a flow rate of 3,000 nl/min and resolved at 500 nl/min using 75-min linear gradients of 4% to 40% (vol/vol) aqueous ACN with 0.2% (vol/vol) formic acid. The mass spectrometer was operated in data-dependent acquisition mode, recording high-accuracy and high-resolution Orbitrap survey spectra using external mass calibration, with a resolution of 35,000 and m/z range of 400 to 2,000. The 15 most intensely multiply charged ions were sequentially fragmented by HCD fragmentation. After two fragmentations, all precursors selected for dissociation were dynamically excluded for 60 s. Data were processed using Proteome Discoverer 1.4 (Thermo Scientific). The UniProt *Stenotrophomonas* database and all DLP3 proteins were searched using SEQUEST (Thermo Scientific). Search parameters included a precursor mass tolerance of 10 ppm and a fragment mass tolerance of 0.8 Da. Peptides were searched with carbamidomethyl cysteine as a static modification and oxidized methionine and deamidated glutamine and asparagine as dynamic modifications.

Determination of DLP3 Lifestyle {#S2.SS9}
-------------------------------

Top agar overlay plates showing confluent lysis of D1571 by DLP3 were used to obtain resistant colonies. Briefly, 3 ml of SM was added to the plates and a sterile glass rod was used to gently skim the agar. The SM was collected and placed into microcentrifuge tubes, then centrifuged at 5,000 × *g* for 5 min. The supernatant was discarded and 1 ml of fresh SM was added to resuspend the pellet, followed by centrifugation at 5,000 × *g* for 5 min. This wash step was repeated three times in total. Following the final wash centrifugation, the supernatant was removed and the pellet was resuspended in 500 μl LB broth. Cells were serially diluted with LB and plated on LB plates, then incubated at 30°C for 16 h. Single colony isolates were selected for further study and tested for superinfection resistance using overnight cultures of every isolate in a top agar overlay assay with DLP3. After an 18 h incubation at 30°C, the plates were observed for plaque development. Single colony isolates without plaque development were retained for analysis.

Erm Functionality {#S2.SS10}
-----------------

Triplicate minimal inhibitory concentration (MIC) experiments on *S. maltophilia* strains D1571 and D1571:DLP3 were conducted using established protocols ([@B108]) to study the functionality of the DLP3-encoded Erm. Overnight cultures were grown at 30°C in 5 mL LB. A 1:100 subculture was grown at 30°C to an OD~600~ of 0.1 in Mueller-Hinton broth (MH) and used in 96 well plates containing an erythromycin dilution series (MP Biomedicals). Following a 16 h incubation, OD~600~ absorbance was obtained using a Wallac 1420 VICTOR2 multilabel counter (PerkinElmer, Waltham, MA, United States) and values were averaged using Excel. Statistical analysis was conducted using GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, United States) to perform a two-way analysis of variance (ANOVA) with Sidak's multiple comparisons.

Growth Analysis of Wild Type D1571 and the DLP3 Lysogen {#S2.SS11}
-------------------------------------------------------

Single colony triplicate overnight cultures of wild type D1571 and the lysogen D1571:DLP3 were grown in LB broth at 30°C with shaking. Subcultures (1:100) for each sample were performed using LB broth and each subculture was grown to an OD~600~ of ∼0.32 at 30°C with 225 RPM shaking. Subcultures were distributed in triplicate aliquots of 200 μl in 96 well plates; an LB broth control was included for each plate. The OD~600~ was then obtained for each plate using a Wallac 1420 VICTOR^2^ multilabel counter (PerkinElmer, Waltham, MA) at the following time points: 0, 2, 4, 6, 8 h. The OD~600~ data were used to determine the growth rate (μ) with the established formula: log~10~ *N* − log~10~ *N*~0~ = (μ/2.303) (*t* − *t*~0~), whereby *N*~0~ is the time zero (*t*~0~) OD~600~ reading and *N* is the final OD~600~ reading obtained at a specific time (*t*) in the experiment. Resulting data were analyzed with GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, United States) to graph the growth curve and growth rate. Statistical analysis of the growth curve and growth rate data were performed in GraphPad Prism 8 using two-way repeated measurement ANOVA with multiple comparisons (Sidak's).

*Galleria mellonella* Killing and Phage Rescue Assays {#S2.SS12}
-----------------------------------------------------

*G. mellonella* infections were performed as previously described, with modifications ([@B95]; [@B51]). Single colony triplicate overnight cultures of wildtype strain D1571 and the DLP3 lysogen, D1571:DLP3, were grown aerobically at 37°C in LB for 19 h corresponding to approximately 2 × 10^10^CFU/mL. Cultures were standardized by OD~600~, washed once in 1× phosphate-buffered saline (PBS, pH 7.4) and serially diluted tenfold in PBS. *G. mellonella* larvae were bred in-house at 30°C using artificial food (wheat germ: 264 g, brewer's yeast: 132 g, beeswax: 210 g, glycerol: 132 g, honey: 132 g, water: 66 g) and larvae weighing approximately 250 mg were selected for experiments. Each experiment consisted of ten larvae per group and 5 μL aliquots of bacterial culture were injected into the rear left proleg of each larva using a 250 μL Hamilton syringe fitted with a repeating dispenser. Sterile PBS injected larvae were used as negative controls and showed 100% survival for the duration of the experiment. Colony counts on LB agar were used to determine the CFUs injected. Following injection, larvae were placed in a static incubator in the dark at 37°C and scored for death every 24 h until 120 h post-infection (hpi). Larvae were considered dead when they did not respond to touch with movement.

For DLP3 phage rescue trials, wildtype D1571 culture was prepared as described above and an inoculum of approximately 8 × 10^6^CFU/larvae was chosen. DLP3 lysate was used at 8.9 × 10^10^ PFU/mL. Larvae were injected with 10 μL of DLP3 lysate dilutions to give MOIs of approximately 100 and 50 into the rear right proleg 1.5 hpi with D1571. Aliquots of 5 μL PBS and 10 μL SM were used in place of bacteria and phage, respectively, for negative controls. Each worm was therefore injected with 15 μL total volume. Larvae were incubated and scored for survival as above. Results from three separate trials were combined and survival at each timepoint was plotted using the Kaplan--Meier method with error bars for standard error using GraphPad Prism 8. Statistical analysis of survival differences was completed using the Log-rank (Mantel--Cox) test.

Results and Discussion {#S3}
======================

Isolation, Morphology, Host Range, and RFLP Analysis {#S3.SS1}
----------------------------------------------------

Bacteriophage DLP3 (vB_SmaS-DLP_3) was isolated from soil using clinical *S. maltophilia* strain D1571. Transmission electron microscopy (TEM) enabled the classification of DLP3 as a *Siphoviridae* of the B1 morphotype ([@B1]) due to the long, non-contractile tail averaging 202.2 ± 5.7 nm and isometric capsid with a length and width of 92.8 ± 4.1 and 84.0 ± 2.8 nm, respectively ([Figure 1](#F1){ref-type="fig"}). No tail fibers were observed in the TEM images. The host range of DLP3 against all 29 clinical *S. maltophilia* isolates reveals a broad tropism through the successful infection of 22 strains, although DLP3 is not capable of infecting the *P. aeruginosa* strains tested ([Table 1](#T1){ref-type="table"}). The restriction fragment length polymorphism analysis revealed DLP3 genomic DNA is resistant to the 15 restriction enzymes screened. These results suggest DLP3 contains modified DNA, although the exact types of modifications are currently undetermined.

![DLP3 *Siphoviridae* morphology. Phage lysate was applied to a carbon-coated copper grid and stained with 4% uranyl acetate. Transmission electron micrographs were obtained at 180,000× magnification. A *S. maltophilia* D1571 pili is shown to be interacting with the baseplate portion of the DLP3 tail. The averaged measurements for tail length, capsid length and width from ten virions is 202, 92, and 84 nm, respectively.](fmicb-11-01358-g001){#F1}

###### 

Host range analysis for *S. maltophilia* bacteriophage DLP3 on *S. maltophilia* and *P. aeruginosa* strains.

  *S. maltophilia* strain      Efficiency of plating
  ---------------------------- -----------------------
  101                          ++
  102^*b*^                     +++
  103                          ++
  152                          −
  155                          ++++
  174                          ++
  176                          ++++
  213                          ++
  214                          ++
  217                          −
  218                          \+
  219                          +++
  230                          ++++
  236                          \+
  242                          ++
  249^*b*^                     \+
  278                          −
  280                          +++
  282                          \+
  287                          ++
  446                          −
  667                          \+
  D1585^a^                     +++
  D1571^a,b^                   ++++
  D1614^a,b^                   −
  D1576^a,b^                   +++
  D1568^a^                     −
  SMDP92^b^                    ++++
  ATCC13637                    −
  ***P. aeruginosa* strain**   
  PA01                         −
  HER1004                      −
  HER1012                      −
  14715                        −
  Utah3                        −
  Utah4                        −
  14655                        −
  6106                         −
  pSHU-OTE                     −
  D1606D^a^                    −
  D1615C^a^                    −
  D1619M^a^                    −
  D1620E^a^                    −
  D1623C^a^                    −
  ENV003^a^                    −
  ENV009^a^                    −
  FC0507^a^                    −
  R285                         −
  14672                        −

−, no sensitivity to phage; +, plaques at 10--2; ++, clearing at 10--2; +++, plaques at 10--4; ++++, plaques at 10--6.

a

Isolates from the Canadian

Burkholderia cepacia

complex Research Referral Repository.

b

Strain susceptible to phage DLP5.

Genomic Characterization {#S3.SS2}
------------------------

The DLP3 genome is 96,852 bp long with a 58.3% global GC content. No low coverage or ambiguous regions were identified with the assembled contig, which has a mean coverage of 114 and a Q40 of 99.6%. NCBI non-redundant protein sequence database searches indicate that DLP3 shares a high identity to the *Siphoviridae* phage vB_SmaS_DLP_5 (DLP5) ([@B76]). DLP5 is the type species of the new genus *Delepquintavirus* and based on the genomic similarities between DLP3 and DLP5, DLP3 is also a member of this new genus. Open reading frame calling with Glimmer and GeneMarkS identified a total of 148 protein coding domain sequences (CDS) covering 95% of the genome ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). DLP3 also encodes five tRNA genes with different specificities: Tyr (GTA), Sup (CTA), Ser (GCT), Ile (GAT), Glu (TTC). A total of 97 proteins could not be assigned functions due to lack of significant results from both BLASTp and CD-Search. The DLP3 genome with putative gene annotations has been deposited in GenBank under accession number [MT110073](MT110073).

![Genome map of DLP3. Scale in bp is shown on the outer periphery. Predicted functions are grouped by color: teal; moron, gray; hypothetical, light blue; DNA packaging, pink; tRNA, red; lysis, green; virion morphogenesis, dark blue; DNA replication and repair, purple; auxiliary metabolism, and yellow; regulatory.](fmicb-11-01358-g002){#F2}

###### 

Genome annotations for DLP3 obtained from BLASTp and CD-Search data.

  CDS   Interval       Length (AA)   Putative function                                                 Species              Coverage (%)   *E*-Value   Identity (%)   Accession
  ----- -------------- ------------- ----------------------------------------------------------------- -------------------- -------------- ----------- -------------- ----------------------------------
  1     48--1856       602           Portal protein                                                    DLP5^a^              98             0           83             [ATS92275.1](ATS92275.1)
  2     1856--3193     445           ParB-like nuclease domain protein                                 DLP5                 100            0           75             [ATS92281.1](ATS92281.1)
  3     3249--3854     201           Serine protease                                                   DLP5                 98             1.00E-113   80             [ATS92325.1](ATS92325.1)
  4     3847--4017     56            Hypothetical protein gp_005                                       DLP5                 100            3.00E-24    77             [ATS92409.1](ATS92409.1)
  5     4090--5307     405           Hypothetical protein gp_006                                       DLP5                 100            0           79             [ATS92283.1](ATS92283.1)
  6     5340--6272     310           Major capsid protein                                              DLP5                 100            0           93             [ATS92299.1](ATS92299.1)
  7     6358--6624     88            Hypothetical protein gp_008                                       DLP5                 100            3.00E-33    65             [ATS92383.1](ATS92383.1)
  8     6693--7436     247           Ribonuclease E                                                    DLP5                 100            3.00E-113   73             [ATS92315.1](ATS92315.1)
  9     7457--8068     203           Hypothetical protein gp_010                                       DLP5                 100            2.00E-121   82             [ATS92324.1](ATS92324.1)
  10    8068--8493     141           Tail protein                                                      DLP5                 99             6.00E-71    77             [ATS92347.1](ATS92347.1)
  11    8490--8936     148           Hypothetical protein gp_012                                       DLP5                 99             3.00E-82    76             [ATS92342.1](ATS92342.1)
  12    9012--9305     97            Hypothetical protein gp_013                                       DLP5                 100            5.00E-50    85             [ATS92376.1](ATS92376.1)
  13    9316--9693     125           Hypothetical protein gp_014                                       DLP5                 100            4.00E-48    67             [ATS92360.1](ATS92360.1)
  14    9693--10448    251           Hypothetical protein gp_015                                       DLP5                 100            2.00E-152   82             [ATS92314.1](ATS92314.1)
  15    10465--10959   164           Hypothetical protein gp_016                                       DLP5                 100            9.00E-83    81             [ATS92333.1](ATS92333.1)
  16    11016--11144   42            Hypothetical protein gp_017                                       DLP5                 95             2.00E-15    83             [ATS92415.1](ATS92415.1)
  17    11151--14915   1254          Tape measure protein                                              DLP5                 99             0           83             [ATS92270.1](ATS92270.1)
  18    14917--16500   527           Hypothetical protein gp_019                                       DLP5                 100            0           79             [ATS92277.1](ATS92277.1)
  19    16500--17474   324           Hypothetical protein gp_020                                       DLP5                 100            0           83             [ATS92295.1](ATS92295.1)
  20    17474--19153   559           Hypothetical protein gp_021                                       DLP5                 100            0           74             [ATS92276.1](ATS92276.1)
  21    19150--19968   272           Minor tail protein                                                DLP5                 100            0           90             [ATS92307.1](ATS92307.1)
  22    19968--20255   95            Hypothetical protein gp_023                                       DLP5                 100            5.00E-62    98             [ATS92377.1](ATS92377.1)
  23    20252--20455   67            Hypothetical protein gp_024                                       DLP5                 100            1.00E-38    93             [ATS92399.1](ATS92399.1)
  24    20445--22925   826           Tail protein                                                      DLP5                 100            0           86             [ATS92271.1](ATS92271.1)
  25    22925--23923   332           Tail assembly protein                                             DLP5                 100            0           86             [ATS92294.1](ATS92294.1)
  26    23926--24102   58            Tail assembly protein                                             DLP5                 100            3.00E-30    88             [ATS92406.1](ATS92406.1)
  27    24110--25081   323           Tail assembly protein                                             DLP5                 100            2.00E-169   70             [ATS92296.1](ATS92296.1)
  28    25085--26107   340           Tail protein                                                      Salvo^b^             100            3.00E-76    43             [AHB12239.1](AHB12239.1)
  29    26183--26611   142           Hypothetical protein gp_030                                       DLP5                 100            1.00E-91    93             [ATS92345.1](ATS92345.1)
  30    26611--27096   161           Hypothetical protein gp_031                                       DLP5                 100            6.00E-87    91             [ATS92334.1](ATS92334.1)
  31    27096--27653   185           Lysozyme                                                          DLP5                 100            2.00E-120   89             [ATS92330.1](ATS92330.1)
  32    27655--28059   134           Hypothetical protein gp_033                                       DLP5                 100            3.00E-80    88             [ATS92352.1](ATS92352.1)
  33    28110--28280   56            Hypothetical protein gp_034                                       DLP5                 78             1.00E-11    70             [ATS92408.1](ATS92408.1)
  34    28329--28715   128           DUF2500 containing protein                                        DLP5                 100            3.00E-77    89             [ATS92350.1](ATS92350.1)
  35    28687--28974   95            Hypothetical protein gp_036                                       DLP5                 93             2.00E-57    96             [ATS92380.1](ATS92380.1)
  36    29077--29271   64            Hypothetical protein                                                                                                             
  37    29275--29574   99            Hypothetical protein gp_041                                       DLP5                 95             2.00E-58    95             [ATS92374.1](ATS92374.1)
  38    29634--30791   385           Hypothetical protein gp_042                                       DLP5                 100            0           78             [ATS92287.1](ATS92287.1)
  39    30898--31506   202           Hypothetical protein gp_043                                       DLP5                 87             2.00E-82    70             [ATS92323.1](ATS92323.1)
  40    31499--31951   150           Phosphoglycerate kinase                                           DLP5                 100            2.00E-103   96             [ATS92341.1](ATS92341.1)
  41    31951--32136   61            Hypothetical protein gp_046                                       DLP5                 100            2.00E-25    79             [ATS92401.1](ATS92401.1)
  42    32197--33141   314           Hypothetical protein gp_047                                       DLP5                 100            3.00E-138   85             [ATS92300.1](ATS92300.1)
  43    33255--34856   533           Hypothetical protein gp_048                                       DLP5                 98             2.00E-156   50             [ATS92279.1](ATS92279.1)
  44    34856--35137   93            Hypothetical protein gp_049                                       DLP5                 100            5.00E-35    64             [ATS92378.1](ATS92378.1)
  45    35139--36056   305           Hypothetical protein gp_050                                       DLP5                 100            0           90             [ATS92301.1](ATS92301.1)
  46    36060--36251   63            Hypothetical protein                                              BCC^c^               98             5.00E-08    46             [WP_046196969.1](WP_046196969.1)
  47    36389--36571   60            Hypothetical protein gp_052                                       DLP5                 85             1.00E-19    78             [ATS92407.1](ATS92407.1)
  48    36568--37128   186           Hypothetical protein gp_053                                       DLP5                 100            5.00E-128   93             [ATS92329.1](ATS92329.1)
  49    37125--38414   429           Helicase                                                          DLP5                 100            0           90             [ATS92282.1](ATS92282.1)
  50    38481--38981   166           Hypothetical protein gp_055                                       DLP5                 100            2.00E-86    80             [ATS92331.1](ATS92331.1)
  51    38974--39957   327           Primase                                                           DLP5                 100            0           77             [ATS92297.1](ATS92297.1)
  52    40036--40812   258           Hypothetical protein gp_057                                       DLP5                 100            3.00E-157   89             [ATS92312.1](ATS92312.1)
  53    40860--41075   71            Hypothetical protein gp_058                                       DLP5                 100            4.00E-41    92             [ATS92395.1](ATS92395.1)
  54    41072--42430   452           Superfamily II DNA or RNA helicase                                DLP5                 100            0           90             [ATS92280.1](ATS92280.1)
  55    42427--42828   133           Transcriptional regulator                                         DLP5                 100            6.00E-68    74             [ATS92353.1](ATS92353.1)
  56    42831--43208   125           Hypothetical protein gp_061                                       DLP5                 100            1.00E-62    81             [ATS92362.1](ATS92362.1)
  57    43208--44425   405           RecA                                                              DLP5                 100            0           90             [ATS92285.1](ATS92285.1)
  58    44425--44799   124           Hypothetical protein gp_063                                       DLP5                 100            9.00E-83    94             [ATS92359.1](ATS92359.1)
  59    44799--45680   293           Hypothetical protein gp_064                                       DLP5                 100            0           87             [ATS92304.1](ATS92304.1)
  60    45677--46174   165           RuvC                                                              DLP5                 99             5.00E-111   93             [ATS92332.1](ATS92332.1)
  61    46152--46766   204           Hypothetical protein gp_066                                       DLP5                 100            5.00E-108   78             [ATS92321.1](ATS92321.1)
  62    46848--47657   269           Hypothetical protein gp_067                                       DLP5                 96             2.00E-153   83             [ATS92308.1](ATS92308.1)
  63    47840--47947   35            Hypothetical protein gp_069                                       DLP5                 100            5.00E-13    94             [ATS92417.1](ATS92417.1)
  64    48028--48504   158           Hypothetical protein gp_070                                       DLP5                 100            3.00E-96    91             [ATS92336.1](ATS92336.1)
  65    48839--49174   111           Hypothetical protein gp_071                                       DLP5                 100            8.00E-60    82             [ATS92357.1](ATS92357.1)
  66    50468--51409   313           Hypothetical protein gp_073                                       DLP5                 100            6.00E-127   61             [ATS92313.1](ATS92313.1)
  67    51397--51585   62            Hypothetical protein                                                                                                             
  68    51582--52145   187           Hypothetical protein gp_074                                       DLP5                 100            2.00E-124   91             [ATS92328.1](ATS92328.1)
  69    52165--52959   264           SPFH domain-containing protein                                    DLP5                 100            0           96             [ATS92309.1](ATS92309.1)
  70    53058--53210   50            Hypothetical proteins                                                                                                            
  71    53207--53653   148           Hypothetical protein gp_077                                       DLP5                 100            3.00E-87    87             [ATS92343.1](ATS92343.1)
  72    53650--54000   116           Hypothetical protein gp_078                                       DLP5                 100            7.00E-74    90             [ATS92365.1](ATS92365.1)
  73    53993--55207   404           Hypothetical protein gp_079                                       DLP5                 100            7.00E-96    44             [ATS92288.1](ATS92288.1)
  74    55279--55548   113           Hypothetical protein gp_081                                       DLP5                 100            1.00E-65    84             [ATS92368.1](ATS92368.1)
  75    55558--55899   89            Hypothetical protein gp_080                                       DLP5                 98             8.00E-37    66             [ATS92369.1](ATS92369.1)
  76    55887--56930   347           UDP-glucose 4-epimerase                                           DLP5                 100            0           83             [ATS92289.1](ATS92289.1)
  77    56962--57285   107           Hypothetical protein gp_083                                       DLP5                 99             9.00E-56    78             [ATS92370.1](ATS92370.1)
  78    57355--58425   356           Hypothetical protein gp_084                                       DLP5                 100            0           73             [ATS92290.1](ATS92290.1)
  79    58418--58939   173           Hypothetical protein gp_087                                       DLP5                 45             6.00E-35    73             [ATS92388.1](ATS92388.1)
  80    58936--59283   115           Hypothetical protein gp_086                                       DLP5                 86             1.00E-36    64             [ATS92361.1](ATS92361.1)
  81    59280--59456   58            Hypothetical protein gp_088                                       DLP5                 100            4.00E-17    62             [ATS92405.1](ATS92405.1)
  82    59465--59737   90            Hypothetical protein BV378_14040                                  *Nostoc* sp. RF31Y   97             8.00E-19    50             [OUL25853.1](OUL25853.1)
  83    59737--59862   41            Hypothetical protein                                                                                                             
  84    59859--60128   89            Hypothetical protein                                                                                                             
  85    60132--60314   60            Hypothetical protein gp_089                                       DLP5                 100            2.00E-05    53             [ATS92403.1](ATS92403.1)
  86    60318--60737   139           Hypothetical protein gp_090                                       DLP5                 84             3.00E-64    79             [ATS92363.1](ATS92363.1)
  87    60734--61210   158           Hypothetical protein gp_091                                       DLP5                 98             7.00E-60    62             [ATS92339.1](ATS92339.1)
  88    61207--61458   83            Hypothetical protein gp_092                                       DLP5                 100            1.00E-22    46             [ATS92382.1](ATS92382.1)
  89    61455--61709   84            Hypothetical protein                                                                                                             
  90    61709--62359   216           Hypothetical protein gp_093                                       DLP5                 100            3.00E-100   65             [ATS92319.1](ATS92319.1)
  91    62362--62649   95            Hypothetical protein gp_094                                       DLP5                 96             4.00E-35    66             [ATS92381.1](ATS92381.1)
  92    62646--62885   79            Hypothetical protein gp_095                                       DLP5                 100            4.00E-31    70             [ATS92392.1](ATS92392.1)
  93    63161--63688   175           Rhomboid membrane protein                                         DLP5                 100            9.00E-96    78             [ATS92322.1](ATS92322.1)
  94    63746--64342   198           Hypothetical protein gp_097                                       DLP5                 98             8.00E-108   82             [ATS92326.1](ATS92326.1)
  95    64339--64593   84            Hypothetical protein gp_098                                       DLP5                 96             3.00E-31    68             [ATS92385.1](ATS92385.1)
  96    64670--65308   212           PIG-L family deacetylase                                          DLP5                 100            6.00E-114   75             [ATS92320.1](ATS92320.1)
  97    65311--66252   313           WcaG                                                              DLP5                 100            0           95             [ATS92298.1](ATS92298.1)
  98    66252--67298   348           WecE                                                              DLP5                 100            0           87             [ATS92291.1](ATS92291.1)
  99    67295--67975   226           Methyltransferase                                                 DLP5                 100            1.00E-139   82             [ATS92317.1](ATS92317.1)
  100   68043--68228   61            Hypothetical protein gp_103                                       DLP5                 98             5.00E-20    62             [ATS92400.1](ATS92400.1)
  101   68225--68647   140           Hypothetical protein gp_104                                       DLP5                 97             8.00E-56    68             [ATS92346.1](ATS92346.1)
  102   68647--70095   482           *N*-acetyl-alpha-[D]{.smallcaps}-glucosaminyl l-malate synthase   DLP5                 100            0           93             [ATS92278.1](ATS92278.1)
  103   70092--70403   103           Hypothetical protein gp_106                                       DLP5                 100            1.00E-36    59             [ATS92372.1](ATS92372.1)
  104   70375--71229   284           ParBc                                                             DLP5                 99             0           89             [ATS92305.1](ATS92305.1)
  105   71229--71879   216           Hypothetical protein gp_108                                       DLP5                 99             5.00E-125   85             [ATS92318.1](ATS92318.1)
  106   71842--73755   637           Terminase large subunit                                           DLP5                 100            0           91             [ATS92274.1](ATS92274.1)
  107   73767--74660   297           Hypothetical protein gp_110                                       DLP5                 100            0           95             [ATS92303.1](ATS92303.1)
  108   74657--75067   136           DUF3310 containing protein                                        DLP5                 100            1.00E-61    71             [ATS92351.1](ATS92351.1)
  109   75129--75371   80            Hypothetical protein gp_112                                       DLP5                 100            8.00E-37    74             [ATS92390.1](ATS92390.1)
  110   75373--75765   130           Hypothetical protein gp_113                                       DLP5                 92             7.00E-12    34             [ATS92355.1](ATS92355.1)
  111   75841--75939   32            Hypothetical protein gp_114                                       DLP5                 100            7.00E-09    81             [ATS92418.1](ATS92418.1)
  112   75936--76253   105           Hypothetical protein gp_115                                       DLP5                 96             6.00E-54    81             [ATS92371.1](ATS92371.1)
  113   76250--76504   84            Hypothetical protein gp_116                                       DLP5                 100            2.00E-42    79             [ATS92387.1](ATS92387.1)
  114   76494--76859   121           Hypothetical protein gp_117                                       DLP5                 98             6.00E-59    80             [ATS92358.1](ATS92358.1)
  115   76859--77011   50            Hypothetical protein gp_118                                       DLP5                 100            1.00E-22    88             [ATS92412.1](ATS92412.1)
  116   77087--77335   82            Hypothetical protein gp_119                                       DLP5                 100            2.00E-43    82             [ATS92389.1](ATS92389.1)
  117   77389--78528   379           Hypothetical protein gp_120                                       DLP5                 70             2.00E-143   94             [ATS92286.1](ATS92286.1)
  118   78528--78878   116           Hypothetical protein gp_121                                       DLP5                 99             4.00E-71    90             [ATS92364.1](ATS92364.1)
  119   78904--79365   153           Hypothetical protein gp_122                                       DLP5                 100            7.00E-78    75             [ATS92340.1](ATS92340.1)
  120   79331--79561   76            Hypothetical protein gp_123                                       DLP5                 100            3.00E-33    76             [ATS92393.1](ATS92393.1)
  121   79558--79731   57            Hypothetical protein gp_124                                       DLP5                 96             6.00E-23    78             [ATS92404.1](ATS92404.1)
  122   79804--79920   38            Hypothetical protein                                                                                                             
  123   79920--80228   102           Hypothetical protein gp_125                                       DLP5                 100            3.00E-59    87             [ATS92373.1](ATS92373.1)
  124   80254--80988   244           Hypothetical protein gp_126                                       DLP5                 100            8.00E-153   83             [ATS92316.1](ATS92316.1)
  125   80985--81350   121           Hypothetical protein gp_127                                       DLP5                 96             1.00E-64    79             [ATS92356.1](ATS92356.1)
  126   81347--81523   58            Hypothetical protein                                                                                                             
  127   81516--81698   60            Hypothetical protein gp_128                                       DLP5                 96             2.00E-29    86             [ATS92402.1](ATS92402.1)
  128   81698--82180   160           DUF1643 containing protein                                        DLP5                 100            2.00E-88    80             [ATS92337.1](ATS92337.1)
  129   82180--82515   111           Hypothetical protein gp_130                                       DLP5                 90             2.00E-44    83             [ATS92367.1](ATS92367.1)
  130   82589--83485   298           DNA ligase                                                        DLP5                 100            0           92             [ATS92302.1](ATS92302.1)
  131   83482--83895   137           Hypothetical protein gp_133                                       DLP5                 100            4.00E-65    74             [ATS92349.1](ATS92349.1)
  132   83895--84197   100           Hypothetical protein gp_134                                       DLP5                 97             2.00E-47    77             [ATS92375.1](ATS92375.1)
  133   84248--85459   403           Hypothetical protein gp_135                                       DLP5                 100            0           81             [ATS92284.1](ATS92284.1)
  134   85456--86028   190           Hypothetical protein gp_136                                       DLP5                 100            3.00E-119   85             [ATS92327.1](ATS92327.1)
  135   86122--88065   647           Pyruvate phosphate dikinase                                       DLP5                 100            0           84             [ATS92273.1](ATS92273.1)
  136   88141--88527   128           Hypothetical protein gp_138                                       DLP5                 98             7.00E-76    90             [ATS92348.1](ATS92348.1)
  137   88527--88868   113           Hypothetical protein gp_139                                       DLP5                 100            5.00E-63    86             [ATS92366.1](ATS92366.1)
  138   88879--89238   119           Transcriptional repressor                                         DLP5                 95             3.00E-71    88             [ATS92354.1](ATS92354.1)
  139   89228--89698   156           Tyrosine phosphatase family protein                               DLP5                 99             5.00E-93    86             [ATS92338.1](ATS92338.1)
  140   89740--90759   339           Hypothetical protein gp_142                                       DLP5                 98             0           77             [ATS92292.1](ATS92292.1)
  141   90756--91532   258           Thymidylate synthase                                              DLP5                 98             6.00E-121   72             [ATS92311.1](ATS92311.1)
  142   91618--92493   291           Hypothetical protein gp_144                                       DLP5                 97             1.00E-124   65             [ATS92306.1](ATS92306.1)
  143   92483--92737   84            Hypothetical protein gp_145                                       DLP5                 97             3.00E-35    71             [ATS92386.1](ATS92386.1)
  144   92734--93231   165           Hypothetical protein gp_146                                       DLP5                 96             1.00E-83    77             [ATS92335.1](ATS92335.1)
  145   93260--95482   740           DNA polymerase I                                                  DLP5                 100            0           85             [ATS92272.1](ATS92272.1)
  146   95794--96030   78            Hypothetical protein                                                                                                             
  147   96134--96415   93            Hypothetical protein gp_149                                       DLP5                 96             6.00E-52    87             [ATS92379.1](ATS92379.1)
  148   96412--96741   109           Hypothetical protein gp_150                                       DLP5                 100            2.00E-61    85             [ATS92310.1](ATS92310.1)

Results below 0.01 were not included and the function was annotated as hypothetical.

a

Stenotrophomonas

phage DLP5,

b

Xylella

phage Salvo, and

c

Burkholderia cepacia

complex.

The CD-Search did yield 37 DLP3 proteins with conserved domains predicted ([Table 3](#T3){ref-type="table"}). Three of the domains identified are domains of unknown function (DUF) which tended to be distributed throughout Gram-negative bacteria and to a lesser extent in Gram-positive bacteria, according to the species distribution for each DUF in pfam ([@B37]). There are six conserved domains (CD) identified which are involved in virion morphogenesis: phage portal protein superfamily, gp1; phage capsid family, gp6; phage tail proteins, gp10 and gp24; laminin G, gp28; and tape measure protein domain, gp17. Nine proteins with domains involved in DNA replication and repair identified with the CD-Search include two ParB domains, gp2 and 104; two helicases, gp49 and 54; Holliday junction resolvase, gp60; RecA recombinase, gp57; topoisomerase primase, gp51; DNA ligase, gp130; and DNA polymerase A, gp145. The remaining CD results appear to be quite diverse in their functions such as the SpoVK family domain involved in sporulation (gp38) ([@B35]), protein-tyrosine phosphatases (gp139 and gp141) typically involved in signal transduction ([@B107]), and a membrane-associated serine protease of the rhomboid family (gp93). One CD identified that is of particular interest is the glycosyltransferase domain of gp102. T-even bacteriophages have been shown to use glycosyltransferases for DNA modification by linking a glycosyl group to hydroxymethyl-cytosine, thus protecting the DNA against digestion by bacterial restriction systems ([@B7]). Another role for glycosyltransferases within bacteriophages is highlighted by some *Shigella* phages which have been shown to seroconvert their host by modifying the *O*-antigen polysaccharides to prevent infection of the bacteria by other O-antigen receptor phages ([@B3]). The specific glycosyltransferase family is RfaB, a protein involved in the assembly of the LPS core of *Escherichia coli* K-12 ([@B82]). This result suggests DLP3 may use the glycosyltransferase to modify the host LPS, similar to the seroconverting *Shigella* phages, though this has yet to be confirmed experimentally.

###### 

The conserved domains found in the 148 DLP3 gene products.

  Gp    Hit type      PSSM-ID   Interval   *E*-Value   Accession                  Short name                                Superfamily
  ----- ------------- --------- ---------- ----------- -------------------------- ----------------------------------------- -------------
  1     Superfamily   327517    29--471    2.89E-49    [cl19194](cl19194)         Phage_portal superfamily                  --
  2     Specific      214678    359--441   8.46E-06    [smart00470](smart00470)   ParB                                      cl02129
  3     Superfamily   317012    5--114     7.39E-23    [cl24270](cl24270)         Peptidase_S78_2 superfamily               --
  6     Superfamily   331903    20--307    5.06E-12    [cl27082](cl27082)         Phage_capsid superfamily                  --
  10    Superfamily   321796    6--137     7.98E-15    [cl02089](cl02089)         Phage_tail_S superfamily                  --
  17    Superfamily   331332    525--930   5.90E-15    [cl26511](cl26511)         Neuromodulin_N superfamily                --
  17    Superfamily   333387    163--230   3.22E-03    [cl28567](cl28567)         HI1514 superfamily                        --
  19    Superfamily   316645    14--69     9.95E-03    [cl16644](cl16644)         DUF4302 superfamily                       --
  21    Superfamily   312753    188--264   8.54E-16    [cl10710](cl10710)         Phage_BR0599 superfamily                  --
  21    Superfamily   331404    18--261    5.62E-12    [cl26583](cl26583)         DUF2163 superfamily                       --
  24    Specific      316107    207--368   2.18E-13    [pfam13550](pfam13550)     Phage-tail_3                              cl26145
  28    Superfamily   328935    62--184    1.13E-05    [cl22861](cl22861)         LamG superfamily                          --
  31    Superfamily   331815    6--185     4.73E-34    [cl26994](cl26994)         Glyco_hydro_108 superfamily               --
  38    Superfamily   332389    92--371    4.11E-42    [cl27568](cl27568)         TIP49 superfamily                         --
  41    Superfamily   332243    13--46     5.11E-03    [cl27422](cl27422)         SecD superfamily                          --
  49    Superfamily   333705    167--405   5.02E-22    [cl28885](cl28885)         RecA-like_NTPases superfamily             --
  51    Superfamily   331610    31--322    7.81E-12    [cl26789](cl26789)         Toprim_N superfamily                      --
  54    Superfamily   331760    51--451    4.03E-38    [cl26939](cl26939)         DEXDc superfamily                         --
  55    Superfamily   322007    53--98     3.22E-04    [cl02600](cl02600)         HTH_MerR-SF superfamily                   --
  57    Superfamily   333705    77--272    2.57E-48    [cl28885](cl28885)         RecA-like_NTPases superfamily             --
  60    Superfamily   328743    1--140     6.73E-14    [cl21482](cl21482)         RuvC_resolvase superfamily                --
  69    Specific      307341    23--207    2.15E-17    [pfam01145](pfam01145)     Band_7                                    cl19107
  76    Specific      224012    1--336     1.19E-76    [COG1087](COG1087)         GalE                                      cl21454
  78    Superfamily   330522    59--126    2.19E-04    [cl25701](cl25701)         RuvB_N superfamily                        --
  93    Superfamily   328780    29--159    3.68E-14    [cl21536](cl21536)         Rhomboid superfamily                      --
  96    Specific      308281    5--122     3.46E-11    [pfam02585](pfam02585)     PIG-L                                     cl00929
  97    Specific      223528    1--297     7.51E-40    [COG0451](COG0451)         WcaG                                      cl25660
  98    Superfamily   327488    20--340    5.46E-56    [cl18945](cl18945)         AAT_I superfamily                         --
  99    Superfamily   327401    30--135    1.43E-04    [cl17173](cl17173)         AdoMet_MTases superfamily                 --
  102   Specific      223515    1--323     4.33E-03    [COG0438](COG0438)         RfaB                                      cl28208
  104   Specific      214678    18--109    7.28E-17    [smart00470](smart00470)   ParB                                      cl02129
  104   Specific      224392    34--187    5.36E-08    [COG1475](COG1475)         Spo0J                                     cl26722
  108   Superfamily   314594    17--68     1.07E-11    [cl13237](cl13237)         DUF3310 superfamily                       --
  128   Specific      311648    12--146    4.16E-44    [pfam07799](pfam07799)     DUF1643                                   cl01787
  130   Superfamily   325160    25--186    2.14E-25    [cl12015](cl12015)         Adenylation_DNA_ligase_like superfamily   --
  130   Superfamily   330238    112--270   1.28E-08    [cl25417](cl25417)         CDC9 superfamily                          --
  133   Superfamily   332389    206--341   8.78E-33    [cl27568](cl27568)         TIP49 superfamily                         --
  133   Superfamily   332204    43--150    8.52E-03    [cl27383](cl27383)         ERCC4 superfamily                         --
  135   Superfamily   331842    16--471    0.00E+00    [cl27021](cl27021)         PtsP superfamily                          --
  139   Superfamily   330819    39--125    1.50E-10    [cl25998](cl25998)         CDC14 superfamily                         --
  141   Superfamily   330819    85--189    1.80E-05    [cl25998](cl25998)         CDC14 superfamily                         --
  145   Superfamily   322025    107--710   7.76E-64    [cl02626](cl02626)         DNA_pol_A superfamily                     --

Phage DLP3 Relatedness to Phage DLP5 {#S3.SS3}
------------------------------------

While characterizing the *Siphoviridae* phage DLP3 genome, it was evident through BLASTn and BLASTp searches that phages DLP3 and DLP5 are closely related. The genome size of DLP3 and DLP5 are similar (96,852 versus 96,542 bp), as is their GC content (58.3 versus 58.4%). BLASTn analysis of DLP3 against DLP5 revealed 81% identity over 90% of the DLP5 genome (0.0 *E*-value). A LASTZ alignment ([@B43]) of the phages using DLP5 as the reference sequence shows sequence identity \>30% between their genomes, represented as a mustard yellow color in the consensus ([Figure 3](#F3){ref-type="fig"}). BLASTn alignment between DLP3 to DLP5 gives a query coverage of 89% and 81% identity. Two small stretches with a breakdown in identity are observed between the DLP5 and DLP3 genomes, which is viewed as a breakdown in the alignment blocks of the dot plot around 30,000 and 60,000 bp ([Figure 3](#F3){ref-type="fig"}). These stretches correspond to four genes (DLP05_037 to DLP05_039, plus DLP05_087) encoding hypothetical proteins with no significant matches in the NCBI database, no conserved domains, and no significant results when using structural prediction software such as HHpred and Phyre. Two additional genes, DLP05_045 and DLP05_068, which encode hypothetical proteins, are not present in the DLP3 genome. The DLP05_045 gene product shares 93% coverage with 36% identity (1.0E-08) to a *Polaromonas naphthalenivorans* hypothetical protein which contains no conserved domains, whereas the DLP05_068 gene product did not have similar sequences in the NCBI database or conserved domains predicted. Both phages encode five tRNAs, with four of the five tRNAs sharing the same specificity: Sup-CTA, Glu-TTC, Ser-GCT, Tyr-GTA. Phage DLP3 differs from DLP5 with respect to the fifth tRNA, which is Ile-GAT in DLP3 but Gly-TCC in DLP5. The amino acid usage of each phage does not explain the differences, as they each have the same usage rates for isoleucine (4.7%) and glycine (7.7%), but there are several nucleotide changes observed in this region when comparing DLP3 to DLP5.

![Genomic alignment of DLP3 to DLP5 using the Large-Scale Genome Alignment Tool. Identity is indicated by color: mustard yellow; \>30%, green; deletion in DLP3, red; deletion in DLP5.](fmicb-11-01358-g003){#F3}

Besides the genomic similarities observed between DLP3 and DLP5, they also share morphological similarities. The DLP3 and DLP5 phages have the same measurement averages for their head width (84 nm) and length (92 nm), as well as tail length (202 nm). The host range of DLP3 versus DLP5 is significantly different, with DLP3 exhibiting a broad host range infecting 22 *S. maltophilia* strains, whereas DLP5 only infects six ([Table 1](#T1){ref-type="table"}). Of the six strains DLP5 is capable of infecting (102, 249, D1571, D1614, D1576, SMDP92), DLP3 is only unable to infect the DLP5 host strain D1614. The virion morphogenesis proteins of DLP3 range in sequence identity to the DLP5 equivalents from 43.8% (gp28) to 93.2% (gp6), with all but gp28 having sequence identity greater than 70%. The gp28 proteins of DLP3 and DLP5 are related to the *Xylella* phage Sano tail fiber protein. The annotation of tail fiber for the Sano protein was based solely on synteny to the *Burkholderia* phage BcepNazgul255. There are no shared conserved domains identified between these two proteins, and the Bcep Nazgul protein is 1,270 amino acids long whereas the DLP3 and DLP5 gp28 proteins and the Sano tail fiber protein are only approximately 340 amino acids long; thus, we consider the assignment of tail fiber function to the Sano phage protein to be incorrect.

The gp28 proteins of DLP3 and DLP5 may play a role in host range due to the variability observed between these proteins. The DLP5 gp28 protein shares 62.5% identity with the Sano tail fiber, while DLP3 only has 39.6% identity to the Sano protein and 41.8% identity to the DLP5 protein. The first 242 N-terminal amino acids of the DLP3 and DLP5 gp28 consensus show a high degree of variability at 24.5% pairwise identity. The remaining 104 amino acids from 243 to the C-terminal have high pairwise identity at 88.5%. Variability in the N-terminal region was also observed with a MUSCLE alignment using all three proteins from DLP3, DLP5 and Sano ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}). The first 258 N-terminal amino acids of the protein consensus share only 35.4% pairwise identity, which increases to 77.8% over the remaining 104 amino acids. The alignment shows at least nine insertion/deletion events have occurred within the DLP3 gene resulting in gaps and insertions in the translated DLP3 protein compared to the Sano and DLP5 proteins. Further investigation into gp28 of DLP3 and DLP5 as a host recognition protein is currently underway to help elucidate whether this protein plays a role in the host range of the *Delepquintavirus* phages.

Receptor Identification {#S3.SS4}
-----------------------

Three *Siphoviridae* phages, DLP1, DLP2 and DLP4, previously isolated on *S. maltophilia* strain D1585, were found to bind the type IV pilus as their cell surface receptor across their host ranges ([@B63]; [@B78]). Despite isolating DLP3 on strain D1571, we assessed DLP3 plaquing ability on the previously constructed D1585 and 280 Δ*pilA* mutants lacking the major pilin subunit. Similar to the three previously characterized phages, *S. maltophilia* strains lacking type IV pili are also resistant to infection by DLP3, shown by an absence of cell lysis at high titer ([Figure 4](#F4){ref-type="fig"}). Complementation with the endogenous genes restores phage infection to wildtype levels. Unfortunately, the *pilA* gene is undetectable in the incompletely assembled D1571 genome, which prevented construction of pili mutants in this background. In contrast to host range data collected when DLP3 was initially isolated from the environment ([Table 1](#T1){ref-type="table"}), DLP3 efficiency of plating on D1585 and 280 is much lower than initially documented, showing phage activity at 10^9^ PFU/mL compared to plaque formation at 10^5^ PFU/mL ([Figure 4](#F4){ref-type="fig"}). We attribute this reduced plaquing ability on some hosts to the repeated propagation of DLP3 on strain D1571. It is hypothesized that propagating DLP3 on a single host has selected for phages optimized to that host over time, resulting in the differences observed.

![DLP3 requires a functional type IV pilus to infect host strains D1585 and 280. Phage DLP3 is capable of infecting wildtype *S. maltophilia* strains D1585 and 280, infecting both at 10^9^ PFU/mL, whereas phage infection is blocked in the Δ*pilA* and Δ*pilT* mutants. Complementation with the endogenous genes restores phage infection to wildtype levels. DLP3 plaquing ability on strain D1571 is shown for titer calculation, however, no mutants were constructed in this background. Images are representative of three biological replicates, each with three technical replicates.](fmicb-11-01358-g004){#F4}

An additional mutant was constructed in strain D1585, Δ*pilT*, lacking the retraction ATPase required for depolymerization of the pilus ([@B20]). This mutation results in hyperpiliated, non-motile cells having numerous non-functional pili projecting from the cell surface. Similar to the Δ*pilA* mutants, D1585 Δ*pilT* is resistant to DLP3 phage infection. This strain grows poorly in liquid, as observed in the speckled overlay lawn, however, this phenotype, as well as susceptibility to phage, is restored by complementation with the *pilT* gene ([Figure 4](#F4){ref-type="fig"}). These results indicate that DLP3 uses the type IV pilus as a cell surface receptor and requires a functional pilus capable of retraction to reach the cell surface for successful host infection. This is the fourth documented *S. maltophilia* phage to use the type IV pilus as its receptor, however, we have yet to identify the receptor for the highly similar phage DLP5. Minor differences in the genomes of these two phages likely explains the significant differences observed in phage host range due to the binding of different receptors.

Analysis of DLP3 Structural Proteins {#S3.SS5}
------------------------------------

To further investigate DLP3 morphology, phage structural proteins were analyzed by HPLC-MS and screened against DLP3 proteins and the *Stenotrophomonas* database in UniProt. The SEQUEST results from searching all DLP3 proteins identified 21 ([Table 4](#T4){ref-type="table"}), though only 11 proteins were classified as virion morphogenesis using BLASTp and CD-Search data ([Supplementary Figure S2](#FS2){ref-type="supplementary-material"}). The most abundant protein isolated was the major capsid protein (gp6), which is the main structural component of a bacteriophage capsid ([@B45]). The second most abundant protein found was the portal protein (gp1), which forms the entry site for phage DNA to be packaged into the capsid by the large terminase. The portal protein also functions like a DNA sensor, measuring the amount of DNA packaged into the capsid and signaling the large terminase to end genome-packaging once full ([@B60]).

###### 

Mass spectrometry protein results with the DLP3 protein database.

  Gp    Function                            Score     Coverage (%)   Unique Peptides   Peptides   PSMs   AAs    MW \[kDa\]   calc. pI
  ----- ----------------------------------- --------- -------------- ----------------- ---------- ------ ------ ------------ ----------
  6     Major capsid protein                1635.14   91.94          27                27         2709   310    33.7         5.76
  14    Hypothetical protein gp_015         189.02    56.57          12                12         282    251    27.4         4.92
  1     Portal protein                      95.51     51.24          35                36         339    566    62.7         5.41
  18    Hypothetical protein gp_019         54.48     19.54          10                10         123    527    58.2         6.27
  17    Tape measure protein                45.75     21.85          28                28         78     1254   131.9        6.39
  27    Tail assembly protein               33.34     28.48          7                 7          46     323    35.4         7.05
  19    DUF4302 family protein              30.84     27.47          7                 7          69     324    35.8         6.61
  24    Tail protein                        23.39     26.51          18                18         106    826    90.1         5.08
  97    WcaG                                22.78     30.99          10                10         52     313    34.8         5.99
  21    Minor tail protein                  11.39     28.68          9                 9          19     272    30.5         7.33
  2     ParB-like nuclease domain protein   11.28     20.45          8                 8          19     445    49.3         6.96
  9     Hypothetical protein gp_010         8.01      31.03          6                 6          11     203    22.5         5.94
  28    Tail protein                        7.74      24.71          10                10         24     340    37.2         8.73
  20    Hypothetical protein gp_021         7.56      14.85          9                 9          30     559    63.5         5.25
  61    Hypothetical protein gp_066         6.45      27.45          7                 7          31     204    22.3         9.00
  25    Tail assembly protein               4.15      23.80          6                 6          15     332    35.5         5.15
  12    Hypothetical protein gp_013         2.37      78.35          4                 4          7      97     9.6          9.47
  3     Serine protease                     2.24      9.95           2                 2          3      201    22.7         4.67
  57    RecA                                2.03      15.56          5                 5          7      405    43.5         6.46
  5     Hypothetical protein gp_006         0.00      6.67           2                 2          4      405    43.4         5.39
  133   ATPase family protein               0.00      10.67          4                 4          9      403    44.6         5.80

Results are ordered by score.

Gene products gp14 and gp18 were also identified. Both gene products are hypothetical proteins without conserved domains. Also, they do not have significant results using HHpred; therefore, their structural function is unknown ([Table 4](#T4){ref-type="table"}). Phyre2 analysis of these proteins only suggested a putative function for gp14, which showed structural identity to the major tropism determinant P1 (MTD-P1) of *Bordetella* phage BPP-1 (38.7% confidence, 25% identity). The MTD-P1 protein in BPP-1 is responsible for phage receptor binding ([@B68]) and uses specific variable residues for target recognition similar to an antibody ([@B67]). Another abundant protein identified is gp24, which is predicted to be a structural component of the DLP3 tail with a phage-tail_3 family (PF13550) conserved domain. The tape measure protein (gp17), which is responsible for setting the tail length ([@B9]), is the largest protein identified and the sixth most abundant, though the ∼130 kDa band was faint after fully destaining ([Supplementary Figure S2](#FS2){ref-type="supplementary-material"}). The remaining DLP3 proteins identified and ordered by relative abundance are gene products gp19, gp97, gp27, gp61, gp20, gp28, gp2, gp21, gp25, gp9, gp133, gp12, gp57, gp5, and gp3. Some of the proteins identified are surprising, such as gp2 (Par-B like nuclease domain protein) and gp5 (RecA), but based on the results obtained by screening the *Stenotrophomonas* protein database, it is evident that there were proteins present from the bacterial cell; thus, there may also be DLP3 proteins present that are not structural in function ([Table 4](#T4){ref-type="table"} and [Supplementary Table S2](#TS2){ref-type="supplementary-material"}).

Lysogenic Conversion of D1571 by Temperate Phage DLP3 {#S3.SS6}
-----------------------------------------------------

Stable DLP3 lysogens of *S. maltophilia* strain D1571 have been isolated and due to the presence of ParB domains in two of the DLP3 proteins, DLP3 may lysogenize its host as a phagemid. The closely related phage DLP5 was also found to encode two proteins with ParB domains and was successfully isolated as a phagemid from the lysogenized strain D1614 ([@B76]). Blastn and PHAST analysis ([@B4]; [@B111]) of GenBank-deposited *Stenotrophomonas* genomes indicates that phage DLP3 (or phages closely related to DLP3) has also lysogenized *S. maltophilia* strains ABB550, FDAARGOS_325 and ICU331. Phage DLP5 has been previously shown to cause lysogenic conversion of *S. maltophilia* strain D1571 ([@B76]). Therefore, we sought to further investigate the characteristics of the D1571:DLP3 lysogen relative to wildtype *S. maltophilia* strain D1571.

Identification of Erythromycin Resistance Factor Erm(45) {#S3.SS7}
--------------------------------------------------------

Annotation of the DLP3 genome revealed the presence of a methyltransferase domain in the gene product encoded by DLP3_099. A specific domain identified is the AdoMet_MTases superfamily comprised of class I S-adenosylmethionine-dependent methyltransferases. The class I family is the largest and most diverse, with members targeting a range of substrate specificities such as small molecules, lipids, nucleic acids, and different target atoms for methylation ([@B98]). Members of this family are known to maintain structural similarity even when the amino acid sequence diverges to as little as 10% ([@B93]). Further investigation into gp69 with HHblits revealed high sequence identity to Erm(45) of *Staphylococcus fleurettii* (HHblits: 100% probability, 2.4e-104 *E*-value). Researchers identified Erm(45) as the enzyme responsible for increased erythromycin resistance in some strains of *S. fleuretti* ([@B109]). The erm gene ([e]{.ul}rythromycin [r]{.ul}ibosome [m]{.ul}ethylase) encodes a methylase enzyme that provides macrolide resistance by methylating the erythromycin target-site on the ribosome ([@B83]). Together, these findings suggested that the DLP3 encoded methyltransferase is an erythromycin resistance protein similar to Erm(45) and could cause an increase in erythromycin resistance of the host cell during lysogeny.

To test the functionality of the DLP3 Erm protein, minimum inhibitory concentration (MIC) assays of the wild type D1571 and lysogen D1571:DLP3 were completed. The results show a statistically significant difference in erythromycin resistance with DLP3 lysogeny over a wide range of concentrations tested ([Figure 5](#F5){ref-type="fig"}). There are differences noted between the wild type and lysogenized strains at lower concentrations of erythromycin, with wild type having a statistically significant increase in optical density at lower concentrations (6 and 34 μg/ml; *P* \< 0.05, 12 and 23 μg/ml; *P* \< 0.01). The cause of the decreased resistance in the lysogen noted at lower concentrations of erythromycin is currently unknown. This trend is reversed at higher concentrations of erythromycin, with the lysogen having significantly higher OD~600~ readings at 144 and 188 μg/ml erythromycin concentrations compared to wild type control (*P* \< 0.0001). The increased resistance noted at higher erythromycin concentrations indicates lysogenic conversion of D1571 by lysogenized DLP3 and confirms the functionality of the predicted Erm protein. Fortuitously, *S. maltophilia* strains are already highly resistant toward macrolides, and macrolides such as erythromycin are not considered to be a frontline treatment option.

![Erythromycin resistance of D1571:DLP3 lysogen increases compared to wild type control D1571. Minimum inhibitory concentration assay was completed in biological and mechanical triplicates. Two-way ANOVA with Sidak's multiple comparisons test was performed on the MIC data. Statistical significance is represented as: \*\*\*\**P* \< 0.0001; \*\**P* \< 0.01; and \**P* \< 0.05.](fmicb-11-01358-g005){#F5}

Differing Growth Characteristics of DLP3 Lysogen *in vitro* {#S3.SS8}
-----------------------------------------------------------

While working with the D1571:DLP3 lysogen and wild type D1571 for the erythromycin resistance assay, it was evident that the lysogen exhibited a faster growth rate as compared to the wild type strain. This difference in growth rate was also observed when growing single colony isolates of the lysogen and wild type on an LB agar plate, with the lysogen having larger single colonies after a 16 h incubation at 30°C as compared to the wild type D1571 (data not shown). To investigate this phenotypic difference further, a growth curve was conducted in mechanical and biological triplicates for the lysogen and wild type over 8 h. The plotted growth curve clearly shows the lysogenized strain exhibiting a faster growth rate than the wild type strain, with significance found following a two-way repeated measures ANOVA with multiple comparisons at 2 h, *P* \< 0.05; 4 h, *P* \< 0.0001; and 6 h, *P* \< 0.01 ([Figure 6A](#F6){ref-type="fig"}). This observation was confirmed by converting the OD~600~ data into growth rate (μ) and plotting the resulting data ([Figure 6B](#F6){ref-type="fig"}). A two-way repeated measures ANOVA with multiple comparisons revealed significant (*P* \< 0.0001) differences between 0- to 2-h and 2- to 4-h time intervals for the lysogen and wild type D1571. The increased growth rate is only observed during the lag and early exponential phase of growth and disappears in the 4- to 6-h and 6- to 8-h growth rate intervals. The cause of the growth rate differences observed with DLP3 lysogenization is currently unknown, though DLP3 does encode many hypothetical and moron genes which may be expressed to produce this phenotype.

![*In vitro* growth analysis of D1571 wild type and D1571:DLP3 lysogen. **(A)** Growth curve of wildtype D1571 compared to D1571:DLP3 strains grown in LB broth over 8 h. Results from biological and mechanical triplicate experiments were averaged and the mean plotted with the standard deviation represented as error bars. **(B)** Growth curve OD~600~ data was converted to the growth rate for wildtype and DLP3 lysogen with the mean plotted and error bars representing standard deviation. Two-way repeated measures ANOVA with multiple comparisons indicates statistical significance (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\*\**P* \< 0.0001).](fmicb-11-01358-g006){#F6}

Virulence of D1571:DLP3 and DLP3 Rescue in *G. mellonella* {#S3.SS9}
----------------------------------------------------------

Based on the differing growth characteristics of D1571:DLP3 lysogen and the wildtype strain, we examined if the increased growth rate of the lysogen observed *in vitro* affected the virulence of strain D1571 *in vivo* using the *G. mellonella* larvae infection model. *G. mellonella* have been used as a non-mammalian eukaryotic model for assessing the virulence of many bacterial pathogens, including *S. maltophilia* ([@B14]; [@B102]; [@B65]), as well as a model to study the efficacy of novel antimicrobial compounds and phages ([@B96]; [@B50]; [@B29]). Injection of *G. mellonella* larvae with *S. maltophilia* D1571 results in dose-dependent killing, with the lethal dose for this strain greater than 10^7^ CFU per larva ([Figure 7A](#F7){ref-type="fig"}). Coinciding with the faster growth rate observed *in vitro*, the D1571:DLP3 lysogen was more virulent than the wildtype D1571 strain, resulting in significantly lower survival for *G. mellonella* larvae injected with 10^7^ (*P* \< 0.01) or 10^6^ (*P* \< 0.001) CFU over 120 h ([Figure 7A](#F7){ref-type="fig"}). This increased virulence may be due to the faster growth rate of D1571:DLP3, however, CFU were not recovered from the larvae following infection.

![Effect of DLP3 on the virulence of D1571 in *G. mellonella.* **(A)** Survival of *G. mellonella* larvae over 120 h following infection with *S. maltophilia* D1571 wildtype or D1571:DLP3 lysogen at varying CFU. Larvae infected with D1571:DLP3 showed significantly lower survival at 10^7^ (\*\**P* \< 0.01) and 10^6^ (\*\*\**P* \< 0.001) CFU than larvae injected with the same inoculum of D1571 (log-rank test). **(B)** Survival of *G. mellonella* larvae injected with 8 × 10^8^CFU of D1571 over 120 h treated with DLP3 at an MOI of 100 (8.9 × 10^8^ PFU), 50 (4.5 × 10^8^ PFU) or 0 at 1.5 h post-infection. For controls, sterile PBS and SM were used in place of bacteria and phage injections, respectively. A significant difference in survival was observed between untreated larvae (MOI 0) and either phage treatment (\*\**P* \< 0.01; log-rank test). Ten larvae were injected per group and results were obtained from three separate trials and plotted using the Kaplan--Meier method with standard error bars.](fmicb-11-01358-g007){#F7}

Despite the DLP3 lysogen showing increased virulence *in vivo*, we sought to determine if DLP3 could rescue *G. mellonella* from wildtype D1571 infection. An inoculum of approximately 10^6^ CFU per larva was chosen to allow for phage rescue at a multiplicity of infection of at least 100, as DLP3 does not propagate higher than 10^10^ PFU/mL. Larvae were injected with DLP3 lysate at 1.5 h post-infection with D1571 and survival monitored over 120 h. Compared to treatment with SM buffer, significantly more larvae survived when given phage at a MOI of 50 or 100 ([Figure 7B](#F7){ref-type="fig"}, *P* \< 0.01), with an average survival at 120 h of 53% or 47% for worms treated at an MOI of 100 or 50, respectively, compared to 17% survival of untreated larvae. Attempts to concentrate DLP3 to a titer greater than 10^12^ PFU/mL without causing melanization of larvae following phage injection were unsuccessful, however, we expect that treatment at a higher MOI would increase the survival of infected larvae. Increased survival may also occur with repeated phage injections over the course of the experiment, however, this was not tested. Overall, this preliminary investigation using *G. mellonella* indicates the potential of DLP3 as a therapeutic for the treatment of *S. maltophilia* infections.

Conclusion {#S4}
==========

The novel temperate phage DLP3 isolated from a soil sample enabled the identification of a second member of the newly established *Delepquintavirus* genus. DLP3 has a genome size of 96,852 bp and a GC content of 58.4%, which is significantly lower than the host strain D1571 which has a GC content of 66.9%. DLP3 encodes two proteins with ParB conserved domains enabling the stable lysogenization of the host strain D1571. Lysogenization by DLP3 leads to a growth rate increase during the lag and early exponential phase of growth for the host when compared to the wild type strain. DLP3 also encodes a functional Erm protein, allowing for the lysogenic conversion of the host D1571 strain which is observed though increased resistance to erythromycin at 144 and 188 μg/ml concentrations. Despite the temperate lifestyle of this phage, DLP3 is capable of lytic activity *in vivo*.

Like DLP3, many of the *S. maltophilia* temperate phages characterized to date feature moron genes that encode virulence factors or antibiotic resistance proteins that could cause lysogenic conversion of their host ([@B41]; [@B39]; [@B76]; [@B78]). Genetically modifying these phages by removing adverse genes, such as those encoding virulence factors or lysogeny proteins, will enable the creation of safe and highly targeted therapeutic agents ([@B61]; [@B31]). Modified phages have been used in a case study against *Mycobacterium abscessus* ([@B31]) and a clinical trial (NCT04191148) sponsored by Locus Bioscience treating urinary tract infections with their modified crPhage cocktail. The genetically modified phage therapy examples set the precedence for other phages, such as DLP3, to be genetically modified and included in therapeutic phage cocktails. To this end, further study of DLP3 receptor binding proteins will possibly allow for the modification of other *S. maltophilia* phages showing therapeutic potential to target a wider host range.
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###### 

MUSCLE multiple sequence alignment of gp28 proteins from phages DLP3 and DLP5, and tail fiber protein of *Xylella* phage Sano. Note the increased amino acid conservation toward the C-termini of the proteins versus the N-termini as observed through protein alignment.
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Click here for additional data file.

###### 

SDS-PAGE gel of DLP3 ghost particles (L) compared to a PageRuler Plus Pre-stained Protein Ladder (Thermo Scientific). Approximate masses are labeled on the right of the gel in kDa. Protein bands labeled using mass spectrometry results from SEQUEST scan of DLP3 and *Stenotrophomonas* protein databases. Stacking and resolving portions of the gel were 4 and 7.5%, respectively. The gel was stained with Coomassie R-250.
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Bacterial strains and plasmids used in this study.
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###### 

Mass spectrometry protein results using the Stenotrophomonas protein database in UniProt. The results are organized by score.

###### 

Click here for additional data file.

[^1]: Edited by: Sutthirat Sitthisak, Naresuan University, Thailand

[^2]: Reviewed by: Kitiya Vongkamjan, Prince of Songkla University, Thailand; Antonia Sagona, University of Warwick, United Kingdom

[^3]: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
